Literature DB >> 8930373

Ibogaine neurotoxicity: a re-evaluation.

H H Molinari1, I M Maisonneuve, S D Glick.   

Abstract

Ibogaine is claimed to be an effective treatment for opiate and stimulant addiction. O'Hearn and Molliver, however, showed that ibogaine causes degeneration of cerebellar Purkinje cells in rats. The present study re-examined cerebellar responses to the high doses of ibogaine used by O'Hearn and Molliver (100 mg/kg or 3 x 100 mg/kg) and sought to determine whether a lower dose (40 mg/kg), one effective in reducing morphine and cocaine self-administration, produced similar responses. Purkinje cell degeneration was evaluated with a Fink-Heimer II stain, and enhanced glial cell activity with an antibody to glial fibrillary acidic protein. Every rat treated with the high dose of ibogaine displayed clear evidence of Purkinje cell degeneration. The degeneration consistently occurred in the intermediate and lateral cerebellum, as well as the vermis. Purkinje cells in lobules 5 and 6 were particularly susceptible. Given the response properties of cells in these lobules, this finding suggests any long-term motor deficits produced by ibogaine-induced degeneration should preferentially affect the head and upper extremity. In marked contrast, rats given the smaller dose of ibogaine displayed no degeneration above the level seen in saline-treated animals. When combined with information on other compounds, these data suggest that the degenerative and "anti-addictive' properties of ibogaine reflect different actions of the drug.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8930373     DOI: 10.1016/0006-8993(96)00739-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis.

Authors:  Jan Carlo Delorenzi; Leonardo Freire-de-Lima; Cerli R Gattass; Deise de Andrade Costa; Liwen He; Martin E Kuehne; Elvira M B Saraiva
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

2.  The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity.

Authors:  E O'Hearn; M E Molliver
Journal:  J Neurosci       Date:  1997-11-15       Impact factor: 6.167

3.  Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.

Authors:  Sebastien Carnicella; Dao-Yao He; Quinn V Yowell; Stanley D Glick; Dorit Ron
Journal:  Addict Biol       Date:  2010-10       Impact factor: 4.280

Review 4.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

5.  Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption.

Authors:  Dao-Yao He; Nancy N H McGough; Ajay Ravindranathan; Jerome Jeanblanc; Marian L Logrip; Khanhky Phamluong; Patricia H Janak; Dorit Ron
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

6.  Cerebellar lingula size and experiential risk factors associated with high levels of alcohol and drug use in young adults.

Authors:  Carl M Anderson; Keren Rabi; Scott E Lukas; Martin H Teicher
Journal:  Cerebellum       Date:  2010-06       Impact factor: 3.847

7.  Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.

Authors:  Thomas Knuijver; Arnt Schellekens; Maarten Belgers; Rogier Donders; Toon van Oosteren; Kees Kramers; Robbert Verkes
Journal:  Addiction       Date:  2021-08-09       Impact factor: 7.256

Review 8.  The anti-addiction drug ibogaine and the heart: a delicate relation.

Authors:  Xaver Koenig; Karlheinz Hilber
Journal:  Molecules       Date:  2015-01-29       Impact factor: 4.411

9.  Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: a study to assess the drug's cardiac ion channel profile.

Authors:  Xaver Koenig; Michael Kovar; Lena Rubi; Agnes K Mike; Peter Lukacs; Vaibhavkumar S Gawali; Hannes Todt; Karlheinz Hilber; Walter Sandtner
Journal:  Toxicol Appl Pharmacol       Date:  2013-05-22       Impact factor: 4.219

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.